Wednesday, October 14, 2015 - 7 p.m. Central European Summer Time
This presentation will describe the IASLC database used for the revision of the current, 7th edition, of the TNM classification for lung cancer. The recommendations of the IASLC Staging and Prognostic Factors Committee for changes in the T, the N and the M components of the classification, and in the stage grouping will be reviewed and discussed.
Monday, October 12, 2015 1 p.m. Eastern Daylight Time / 11 a.m. Mountain Daylight Time
High impact abstracts presented on the topic of lung cancer at both ASCO 2015 and WCLC 2015 will be reviewed. Dr. Waqar will focus on updates in systemic therapy, and Dr. Robinson will focus on updates in radiation therapy. Following the presentations there will be ample opportunity for the audience to submit questions/comments to the faculty and discussion via Internet chat.
Thursday, October 8, 2015 - 6 p.m. British Summer Time
In this program Professor Nicholson will describe the important changes in the 2015 WHO classification of lung tumours, reflecting the numerous advances in tumour genetics and therapy over the past decade. In particular, classification of small biopsies and cytology is provided within the classification for the first time, with emphasis on integration of molecular testing. Changes to classification of other major tumour types will also be presented and discussed, in particular adenocarcinomas where there have been significant revisions since 2004.
Thursday, October 1, 2015 at 9 p.m. Eastern Daylight Time
IASLC continues the Lung Cancer Grand Round Series in 2015 with this LIVE WEBINAR featuring Dr. David R. Gandara.
Friday, September 25, 2015 - 6 p.m. Japan Standard Time / 11 a.m. Central European Summer Time
The IASLC Education Committee is pleased to announce the second program in the 2015 series of Live Webinars presented by the Advanced Radiation Technology Committee. This subcommittee is focused on providing educational and informational programs addressing state of the art radiation therapy for lung cancer. This live program will be moderated by Francoise Mornex, MD, PhD and feature presentations by Yong Chan Ahn, MD, PhD and Yasushi Nagata, M.D., Ph.D.
September 1, 2015 - 7 p.m. CEST - Recording Available
This CME live webinar series is designed to meet the educational needs of healthcare professionals who diagnose and treat patients with lung cancer, including medical oncologists, thoracic surgeons, pulmonologists, radiation oncologists, radiologists, pathologists and advanced practice nurses and physicians' assistants.
Wednesday, August 26, 2015 at 9 p.m. EDT - Recording Available
IASLC continues the Lung Cancer Grand Round Series in 2015 with this LIVE WEBINAR featuring Dr. Lecia Sequist. In this program Dr. Sequist will review the current data about best practices for treatment of stage IV EGFR mutation-positive lung cancer.
Tuesday, July 21, 2015 - 1 p.m. CEST - Recording Available
The IASLC Education Committee is pleased to announce the second program in the 2015 series of Live Webinars presented by the Advanced Radiation Technology Committee. This subcommittee is focused on providing educational and informational programs addressing state of the art radiation therapy for lung cancer. This live program will be moderated by Francoise Mornex, MD, PhD and feature presentations by Dr. David Palma and Professor Suresh Senan.
Monday, July 20, 2015 - 8 p.m. EDT - Recording Available
This seminar will inform participants the outcomes of concurrent chemo-radiotherapy from two phase III randomized trials, which together enrolled more than 1,100 patients. With these results, the focus is now geared towards investigational approaches that merit evaluation in future clinical trials.
Thursday, July 14, 2015 - 6 p.m. BST - Recording Available
In this session, Prof. Keith Kerr updates a webinar first presented last year, on developments in personalized medicine for patients with lung cancer, the impact that this has had, and could have in the future, for those patients, and how the pursuit of biomarkers to predict response to targeted therapy has changed lung cancer diagnostics.